Lamivudine

Lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI), is a cornerstone in the therapeutic landscape for managing HIV-1 and hepatitis B infections. This comprehensive activity explores the diverse indications and contraindications for lamivudine across both conditions, elucidating its mechanism of action as a pivotal component in treating these disorders. Healthcare professionals will gain the necessary knowledge to navigate the nuances of lamivudine usage through a detailed examination of pharmacodynamics, pharmacokinetics, and relevant interactions. The program emphasizes the importance of vigilant monitoring to assess treatment responses and manage potential adverse events effectively, enabling the healthcare team to optimize patient care and outcomes in these infectious diseases.